#2469 - Brigham Buhler - The Joe Rogan Experience Recap

Podcast: The Joe Rogan Experience

Published: 2026-03-18

Duration: 2 hr 28 min

Guests: Brigham Buhler

What Happened

Brigham Buhler discusses the impact of allergens in different regions, noting how moving from Houston's pine trees to Austin's cedar affected his health. He mentions how his body eventually adapted and highlights the benefit of using colostrum to alleviate symptoms.

Brigham Buhler addresses the reclassification of peptides by the FDA, noting that the previous administration labeled them as dangerous without adequate justification. He has submitted 17 FOIA requests to the FDA for clarity on this classification, which have gone unanswered. The current administration, including Secretary Kennedy, is more receptive to the potential benefits of peptides, and Buhler is optimistic about future changes.

Brigham Buhler discusses the misconceptions surrounding testosterone therapy and prostate cancer. He explains that the fear of testosterone causing prostate cancer stems from a 1930s study with a flawed methodology. Modern studies show no correlation between testosterone therapy and increased prostate cancer risk, leading to a potential change in FDA guidelines.

The conversation shifts to the challenges of the current healthcare system. Brigham Buhler argues that the system is focused on treating symptoms rather than preventing chronic diseases. He advocates for a proactive approach to healthcare, emphasizing the importance of personalized medicine and preventative care to enhance healthspan.

Brigham Buhler highlights the role of genetics in personalized medicine. He explains how genetic sequencing can provide insights into an individual's predisposition to certain conditions. By understanding these genetic markers, healthcare providers can tailor treatments to each patient's unique genetic makeup, potentially preventing chronic diseases before they develop.

The potential of Muse stem cells is explored, with Brigham Buhler describing them as a promising advancement in regenerative medicine. These cells are stress-enduring and capable of becoming any type of cell, making them highly versatile for healing various types of tissue damage. The cells have shown no tumorigenic behavior and have been used effectively in trials overseas.

Key Insights

• Brigham Buhler has faced significant challenges with the FDA regarding the classification of peptides. Despite submitting 17 FOIA requests, he has not received responses, fueling his efforts to work with the current administration for change.
• Testosterone therapy has been misunderstood for decades due to a flawed study from the 1930s. Modern research shows no link between testosterone and prostate cancer, prompting the FDA to reconsider its stance on hormone therapy.
• The current healthcare system is criticized for its focus on treating chronic disease symptoms rather than prevention. Brigham Buhler advocates for a shift towards proactive, personalized medicine to enhance healthspan and reduce chronic disease prevalence.
• Muse stem cells represent a breakthrough in regenerative medicine with their ability to differentiate into any cell type without becoming tumorigenic. These cells are being used in trials overseas and hold promise for future medical applications in the U.S.